UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000028845 |
|---|---|
| Receipt number | R000032948 |
| Scientific Title | HLA-haploidentical stem cell transplantation using a low dose ATG and steroid |
| Date of disclosure of the study information | 2017/08/27 |
| Last modified on | 2020/04/05 17:36:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
HLA-haploidentical stem cell transplantation using a low dose ATG and steroid
Acronym
HLA-haploidentical RIST
Scientific Title
HLA-haploidentical stem cell transplantation using a low dose ATG and steroid
Scientific Title:Acronym
HLA-haploidentical RIST
Region
| Japan |
Condition
Condition
acute myeloid leukemia, acute lymphoid leukemia/first or second allogeneic stem cell transplantation
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
HLA-haploidentical stem cell transplantation using a low-dose anti-T-lymphocyte globulin (ATG) and steroid is expected to evert a strong graft-versus-leukemia effect. In the present study, whether this transplant procedure can improve the survival of patients with poor prognosis is analyzed.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
This is a prospective, multi-center (5 transplant centers) study of HLA-haplidentical stem cell transplantation. A hundred patients are planning to be enrolled. The major outcome is survival on day 100.
Key secondary outcomes
1. The incidence and severity of acute GVHD
2. The incidence and severity of chronic GVHD
3. Survival rate at 1 year
4. Disease-free survival rate at 1 year
5. transplant-related mortality at 1 year
6. The incidence of infection (bacterial, fungus, virus, others)
7. Immunological recovery
8. Iron overload
9. The concentration of ATG on days 0 and 7.
10. donor T cell repertoire analysis
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Maneuver |
Interventions/Control_1
Patients with AML or ALL at poor risk undergo transplantation using peripheral blood stem cells from an HLA-haploidsentical donor. The conditioning treatment consists of fludarabine 30 mg/m2/day x 6 (days -9 to -4), melphalan 70 mg/m2/day x 2 (days -3 to -2), thymoglobulin 1.25 mg/kg/day x 2 (days -2 to -1), and total body irradiation 3 Gy on day 0. When patients have bone marrow blasts > 20%, cytarabine 2 g/m2/day x 4 (days -9 to -6) is added. Peripheral blood stem cells containing 3.0-10.0 CD34 cells/kg (patients' body weight) is infused on day 0. GVHD prophylaxis consists of tacrolimus and methylprednisolone 1 mg/kg. Tacrolimus and methylprednisolone are started on day -2 and 0, respectively.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 16 | years-old | <= |
Age-upper limit
| 60 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. A related donor who is matched or 1 antigen-mismatched in HLA-A, -B, and -DR antigen is not available.
2. An unrelated donor who is matched in HLA-A, -B, -DR antigen, and allelic mismatched 0 or 1 locus in HLA-A, -B, -DR loci is not available. When patients is an urgent situation, those are eligible.
3. A related HLA-haploidentical donor is available.
4. Disease status; for AML, any status other than first CR is eligible. Patients with AML in first CR with poor karyotype, MRD positivity, FLT-ITD mutation(+), M0, and induction failure after first induction therapy are eligible. For ALL, patients in any status is eligible.
5. Patients who undergo first or second allogeneic stem cell transplantation are eligible.
6. Performance status is 0 or 1 in ECOG criteria.
7. Patients do not have an organ failure, including heart, lung, liver, and kidney, as follows: 1) Ejection friction >50%, 2) SO2>93%, 3) T bilirubin <2.0 mg/dl and AST <2.5 times the normal upper limit, 4) serum creatinine level <1.5 times the normal upper limit.
Key exclusion criteria
1. A history of adverse events for agents used in the conditioning treatment or GVHD prophylaxis.
2. Active CNS disorders other than leukemia.
3. Active infection.
4. Doctor's decision that patients are inappropriate for this study in some reasons.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroyasu Ogawa |
Organization
Hyogo College of Medicine
Division name
Division of Hematology, Department of Internal Medicine
Zip code
Address
1-1, Mukogawa-machi, Nishinomiya city, Hyogo
TEL
0798-45-6886
ogawah@hyo-med.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hiroyasu Ogawa |
Organization
Hyogo College of Medicine
Division name
Division of Hematology, Department of Internal Medicine
Zip code
Address
1-1, Mukogawa-machi, Nishinomiya city, Hyogo
TEL
0798-45-6886
Homepage URL
ogawah@hyo-med.ac.jp
Sponsor or person
Institute
Hyogo College of Medicine
Institute
Department
Personal name
Funding Source
Organization
Ministry of Education, Culture, Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Saiseikai Maebashi Hospital, Japanese Red Cross Nagoya First Hospital, Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
がん･感染症センター都立駒込病院 (東京都)、群馬県済生会前橋病院 (群馬県)、名古屋第一赤十字病院 (愛知県)、東北大学病院 (宮城県)
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 08 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2017 | Year | 06 | Month | 12 | Day |
Date of IRB
| 2017 | Year | 06 | Month | 12 | Day |
Anticipated trial start date
| 2017 | Year | 08 | Month | 27 | Day |
Last follow-up date
| 2023 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 08 | Month | 26 | Day |
Last modified on
| 2020 | Year | 04 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032948
